Genentech Shares Real-World Vabysmo Data at EURETINA Eye Disease Conference

Genentech presented real-world safety and effectiveness data on its eye drug Vabysmo at a major retinal disease conference.

Genentech announced on October 1, 2026, that it had presented new data on Vabysmo at EURETINA, a major European retinal disease conference. The data focused on the drug's real-world performance across multiple retinal conditions, including its safety and effectiveness outside of controlled clinical trial settings. Vabysmo is Genentech's treatment targeting retinal diseases, and real-world data presentations are a common way for pharmaceutical companies to demonstrate how a drug performs in broader patient populations after initial regulatory approval. EURETINA is one of the premier gatherings for retinal specialists in Europe, making it a notable venue for such disclosures. Both sources reporting on this announcement are wire releases originating from the same Business Wire press release issued by Genentech, headquartered in South San Francisco, California. As a result, the content across both sources is identical, reflecting the company's own characterization of its findings rather than independent journalistic reporting. No specific numerical outcomes, patient population sizes, or comparator data were available in the source material provided, limiting the ability to assess the scope or strength of the findings presented at the conference.

Why it matters

Real-world data on widely used retinal treatments like Vabysmo can influence prescribing decisions for conditions such as wet age-related macular degeneration and diabetic macular edema, which affect millions of patients globally. Post-approval data presentations help establish how drugs perform outside the controlled conditions of clinical trials.

Key facts

• Genentech issued the announcement on October 1, 2026, from South San Francisco, California
• The data was presented at EURETINA, a major European retinal disease conference
• The presentation focused on real-world — not clinical trial — effectiveness and safety data
• Vabysmo is indicated for major retinal conditions, including wet age-related macular degeneration and diabetic macular edema
• Both sources are derived from the same Genentech Business Wire press release, with no independent reporting

Bias & framing notes

Both sources are identical wire releases from a single Genentech-issued press release, meaning all framing originates from the drug's manufacturer. There is no independent journalistic verification, no outside expert commentary, and no specific data figures available in the provided source material. The absence of numerical results or methodology details makes it impossible to evaluate the strength of the findings.

NewsClear — neutral news & congressional tracking · Bill of the Week